In this single-centre , open-label , three-treatment , three-period crossover study ( NCT01504906 ) , healthy volunteers ( n = 26 ) randomly received each of three treatments : cyclosporine ( 600 mg single oral dose ) plus ticagrelor ( 180 mg single oral dose ) ; cyclosporine alone ; ticagrelor alone .